PDCD1 and neoplasm: For instance, inhibition of PD-1/PD-L1 in MHC-I-deficient tumor cells, like most Hodgkin’s lymphomas that express higher levels of PD-L1, resulted in a better response and in a higher NK cell activity in patients [50].